ArticleTherapeutic advances in medical oncology2019

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).

Emanuela Risi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.